/ /

Andrew John Li, MD
Dr. Li is a Fellow in Gynecologic Oncology
Letters to the Editor
Letters discuss the myriad of issues affecting the practice of specialties. Joshua A. Copel responds.
Letters to the Editor
Letters discuss global endometrial ablations, intrauterine scarring, and disagreements over cancer biomarkers. Steven R. Goldstein and Andrew John Li respond.
New biomarkers for ovarian cancer: OVA1 and ROMA in diagnosis
The optimal management of a woman with an ovarian adnexal mass remains a clinical challenge to obstetricians, gynecologists, and other providers who care for women.
Statins and cancer: Discovering their role in treating gynecologic cancers
HMG-CoA reductase inhibitors, commonly referred to as statins, have gained popularity for their ability to effectively lower cholesterol levels in patients with CV disease, but new roles for statins may be on the horizon.
BRCA1 and BRCA2: Genetic testing and intervention strategies
Who should undergo genetic testing? Before ordering it, three conditions should be met: There should be a greater than 10% likelihood of a positive test; the ordering physician should be able to interpret the result; and the information should be used to make management decisions.